Evidence map›Paper›PMID 26613645›Full record

ArticleThe Journal of physiology2016

Dynorphin inhibits basal forebrain cholinergic neurons by pre- and postsynaptic mechanisms.

L L Ferrari, L J Agostinelli, M J Krashes, B B Lowell, T E Scammell, E Arrigoni

Open access · greenAbstract read
In one paragraph

Article in The Journal of physiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. The neurobiological basis of narcolepsy.Nature reviews. Neuroscience · 2019
    Review
  5. Article
  6. Dynorphin Counteracts Orexin in the Paraventricular Nucleus of the Thalamus: Cellular and Behavioral Evidence.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2018
    Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

L L FerrariDepartment of Neurology, Beth Israel Deaconess Medical Center, Boston, MA, 02215, USA.
L J AgostinelliDepartment of Neurology, Beth Israel Deaconess Medical Center, Boston, MA, 02215, USA.
M J KrashesNational Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, MD, 20892-1453, USA.
B B LowellDepartment of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, 02215, USA.
T E ScammellDepartment of Neurology, Beth Israel Deaconess Medical Center, Boston, MA, 02215, USA.
E ArrigoniDepartment of Neurology, Beth Israel Deaconess Medical Center, Boston, MA, 02215, USA.
Beth Israel Deaconess Medical Center · USNational Institute of Diabetes and Digestive and Kidney Diseases · US

Funding

Transgenic CoreP30DK057521 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI FLOREZ, JOSE CARLOS · 2000 to 2019
$31.4M
Wakefulness and Forebrain Activation by Orexin NeuronsP01HL095491 · NHLBI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI WELLMAN, DAVID ANDREW · 2010 to 2019
$25.1M
The routing of hunger/satiety information by the parabrachial nucleus (PBN)R01DK075632 · NIDDK · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BRADFORD B LOWELL · 2006 to 2026
$8.1M
AGRP NEURONS. NMDARs, Spines, Source of Excitatory Input and Downstream EffectorsR01DK096010 · NIDDK · BETH ISRAEL DEACONESS MEDICAL CENTER · PI LOWELL, BRADFORD B · 2012 to 2024
$7.2M
Neurocircuitry Underlying Leptin Regulation of Energy BalanceR01DK089044 · NIDDK · BETH ISRAEL DEACONESS MEDICAL CENTER · PI LOWELL, BRADFORD B · 2010 to 2023
$6.0M
Pontine Control of REM AtoniaR01NS061863 · NINDS · BETH ISRAEL DEACONESS MEDICAL CENTER · PI ARRIGONI, ELDA · 2009 to 2013
$1.9M
Basal forebrain hypothalamic networks supporting wakefulnessR01NS091126 · NINDS · BETH ISRAEL DEACONESS MEDICAL CENTER · PI ARRIGONI, ELDA · 2015 to 2019
$1.9M
Basal Forebrain Corticopetal GABAergic Neurons and Cortical ArousalR21NS082854 · NINDS · BETH ISRAEL DEACONESS MEDICAL CENTER · PI ARRIGONI, ELDA · 2013 to 2014
$476k
NHLBI NIH HHS P01 HL095491NHLBI NIH HHS P01HL095491NIDDK NIH HHS P30 DK057521NIDDK NIH HHS R01 DK075632NIDDK NIH HHS R01 DK089044NIDDK NIH HHS R01 DK096010NINDS NIH HHS R01 NS061863NINDS NIH HHS R01NS061863NINDS NIH HHS R01 NS091126NINDS NIH HHS R01NS091126NINDS NIH HHS R21 NS082854NINDS NIH HHS R21NS082854
6 · The paper itself

Abstract

key pointsThe basal forebrain is an important component of the ascending arousal system and may be a key site through which the orexin neurons promote arousal. It has long been known that orexin-A and -B excite basal forebrain cholinergic neurons, but orexin-producing neurons also make the inhibitory peptide dynorphin. Using whole-cell recordings in brain slices, we found that dynorphin-A directly inhibits basal forebrain cholinergic neurons via κ-opioid receptors, and decreases afferent excitatory synaptic input to these neurons. While the effects of dynorphin-A and orexin-A desensitize over multiple applications, co-application of dynorphin-A and orexin-A produces a sustained response that reverses depending on the membrane potential of basal forebrain cholinergic neurons. At -40 mV the net effect of the co-application is inhibition by dynorphin-A, whereas at -70 mV the excitatory response to orexin-A prevails. ABSTRACT: The basal forebrain (BF) is an essential component of the ascending arousal systems and may be a key site through which the orexin (also known as hypocretin) neurons drive arousal and promote the maintenance of normal wakefulness. All orexin neurons also make dynorphin, and nearly all brain regions innervated by the orexin neurons express kappa opiate receptors, the main receptor for dynorphin. This is remarkable because orexin excites target neurons including BF neurons, but dynorphin has inhibitory effects. We identified the sources of dynorphin input to the magnocellular preoptic nucleus and substantia innominata (MCPO/SI) in mice and determined the effects of dynorphin-A on MCPO/SI cholinergic neurons using patch-clamp recordings in brain slices. We found that the orexin neurons are the main source of dynorphin input to the MCPO/SI region, and dynorphin-A inhibits MCPO/SI cholinergic neurons through κ-opioid receptors by (1) activation of a G protein-coupled inwardly rectifying potassium current, (2) inhibition of a voltage-gated Ca(2+) current and (3) presynaptic depression of the glutamatergic input to these neurons. The responses both to dynorphin-A and to orexin-A desensitize, but co-application of dynorphin-A and orexin-A produces a sustained response. In addition, the polarity of the response to the co-application depends on the membrane potential of BF neurons; at -40 mV the net effect of the co-application is inhibition by dynorphin-A, whereas at -70 mV the excitatory response to orexin-A prevails. This suggests that depending on their state of activation, BF cholinergic neurons can be excited or inhibited by signals from the orexin neurons.

Indexed as

AnimalsCalcium ChannelsCholinergic NeuronsDynorphinsG Protein-Coupled Inwardly-Rectifying Potassium ChannelsMiceMice, Inbred C57BLOrexinsPreoptic AreaReceptors, OpioidSubstantia InnominataSynapsesSynaptic PotentialsCalcium ChannelsDynorphinsG Protein-Coupled Inwardly-Rectifying Potassium ChannelsOrexinsReceptors, Opioid

Identifiers

PMID26613645
PMCPMC4753266
OpenAlexW2182638939

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.